| Date |
Title |
Pages |
Source |
Download |
|
| Apr-25 |
4QFY25 Preview: Focus on Domestic Plus Margin Variance |
9 |
Emkay Research |
 |
|
| Apr-25 |
HSIE Research is also available on Bloomberg ERH HDF & Thomson Reuters Pharma dodges first round of US tariff risk |
8 |
HDFC Securities |
|
|
| Jan-25 |
March of corporate hospitals: Deepening presence |
143 |
Emkay Research |
|
|
| Jan-25 |
US pricing pressure eases; margins improve |
5 |
Nirmal Bang |
|
|
| Jan-25 |
Chemicals/Pharma EXIM trends |
20 |
Phillip Capital |
|
|
| Jan-25 |
3QFY25 Preview: Change in script unlikely |
7 |
Emkay Research |
|
|
| Jan-25 |
Bed additions/ARPOB to drive growth during the quarter |
7 |
Centrum Research |
|
|
| Jan-25 |
US/India to drive Pharma; Volume-led growth to continue for Diagnostics |
8 |
Centrum Research |
|
|
| Jan-25 |
Q3FY25 Preview: Seasonal benefits add to momentum |
6 |
Phillip Capital |
|
|
| |